NECTAR LIFESCIENCES LTD.

Nectar Lifesciences Ltd has announced its 31st Annual General Meeting (AGM) will be held on September 18, 2026, at 11:00 AM IST via video conference. The company is providing a web-link to its Annual Report 2025-26 for members who have not registered their email addresses. Remote e-voting will commence on September 15, 2026, and conclude on September 17, 2026. The cut-off date for the AGM and e-voting is September 11, 2026. The AGM Notice and Annual Report are accessible via provided web links and on the company's and stock exchanges' websites.

Nectar Lifesciences Ltd has announced the details for its 31st Annual General Meeting (AGM), scheduled for September 18, 2026, at 11:00 AM IST. The meeting will be conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM). Key agenda items include the adoption of standalone and consolidated financial statements for the financial year ended March 31, 2026, along with the Directors' and Auditors' reports. Additionally, the AGM will address the re-appointment of Mr. Sanjiv Goyal as a director retiring by rotation and the re-appointment of Dr. Kuldip Kumar Bhasin as an Independent Director for a second term. The company has also included a disclaimer regarding forward-looking statements within its Annual Report.

Nectar Lifesciences Ltd has announced the schedule for its 31st Annual General Meeting (AGM) for the Financial Year 2025-26. The AGM will be held on Friday, September 18, 2026, at 11:00 AM IST via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The company is facilitating remote e-voting for its members, which will commence on Tuesday, September 15, 2026, at 9:00 AM IST and conclude on Thursday, September 17, 2026, at 5:00 PM IST. An Insta Poll facility will also be available at the AGM for members who have not voted remotely. The cutoff date for eligibility for remote e-voting and Insta poll is September 11, 2026. Key agenda items include the adoption of standalone and consolidated financial statements for FY 2025-26, the re-appointment of Mr. Sanjiv Goyal as a director retiring by rotation, and the re-appointment of Dr. Kuldip Kumar Bhasin as an Independent Director for a second term.

Nectar Lifesciences Limited has announced a change in its corporate office location. The board of directors approved the relocation from Plot No. 110, Industrial Area, Phase 1, Chandigarh 160 002 to "Godrej Eternia," West Wing (Tower A), Plot No. 70, Industrial Area, Phase-1, Chandigarh, 160 002. This change will be effective from September 15, 2026. The company has informed the stock exchange and requested that this information be taken on record.

Nectar Lifesciences Ltd has announced that its Annual General Meeting (AGM) will be held on September 18, 2026. The company will observe a book closure period from September 12, 2026, to September 18, 2026, inclusive. This period is for determining shareholder eligibility for voting, including remote e-voting and e-voting at the AGM. The cut-off date for ascertaining eligibility for remote e-voting and AGM voting is September 11, 2026, which is the day before the book closure begins.

Nectar Lifesciences Limited's Board of Directors, in a meeting held on August 14, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also appointed Dr. Gunmala Suri as an Additional Director and Non-Executive Non-Independent Director, subject to member approval. The 31st Annual General Meeting (AGM) is scheduled for September 18, 2026, with the register of members closing from September 12 to September 18. Mr. Sanjiv Goyal will be re-appointed as a director retiring by rotation. Committee compositions for Audit, SRC, and CSR were also reconstituted.

Nectar Lifesciences Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved the appointment of Dr. Gunmala Suri as an Additional Director and Non-Executive Non-Independent Director, subject to member approval. The 31st Annual General Meeting (AGM) is scheduled for September 18, 2026, with the register of members closing from September 12 to September 18, 2026. The re-appointment of Mr. Sanjiv Goyal was also noted. Committee compositions for Audit, SRC, and CSR were reconstituted.

Nectar Lifesciences Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda item for this meeting is the consideration and approval of the Unaudited Financial Results for the quarter ended June 30, 2026. The meeting is being held in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically concerning regulations 29, 30, and 33. This announcement serves as formal notification to the BSE regarding the scheduled board meeting and its financial reporting purpose.

Nectar Lifesciences Ltd. announced the resignation of Dr. Surulichamy Senthilkumar as a Non-Executive Non-Independent Director. The resignation is effective from the closing hours of August 06, 2026, citing pre-occupations and personal reasons. The company has provided the necessary disclosures as per LODR Regulations and SEBI Master Circular. The resignation letter details the reasons and confirms no other material factors influenced the decision.

Nectar Lifesciences Limited has announced an extension for the completion of its slump sale transaction with Capnest Health Care Private Limited. The original disclosures regarding the transfer of business on a slump sale basis were made on December 20, 2025, and April 28, 2026. The parties have now mutually agreed to push the expected completion date to on or before December 31, 2026. All other terms and disclosures related to the slump sale remain unchanged.